Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

“These results, combined with the patient satisfaction with the relative ease of providing blood rather
than a solidtissue sample, suggest a clinical strategy of pursuing plasma NGS first, then tissue NGS if plasma NGS cannot detect relevant mutations.”

Bishal Gyawali, MD, PhD; Howard (Jack) West, MD

Editorial

90% Concordance

with tissue genotyping for targetable alterations before first-line NSCLC therapy

Study Overview

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 can increase the likelihood of finding targetable mutations.

Key findings

44% of eligible patients
were unable to get complete genomic results from tissue biopsy
2x as many patients
had targetable alterations detected by Guardant360 and tissue testing (n=82) versus tissue testing alone (n=47)
86% of patients
had a response or stable disease based on RECIST criteria

Jama oncology featured publication

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

You may also
be interested in...

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

View Publication

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

View Publication